Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.
Mylan Inc
Breaking News
Drugmakers Abbott Laboratories (ABT.N) and Mylan Inc (MYL.O) on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands.
Mylan’s acquisition of a unit at Strides Arcolab Ltd announced July 8 was deferred by Indian regulators.
Subscribe to VCpost newsletter
Most Popular
- Former CEO Shoots Himself to Commit Suicide After Receiving $25 Million Record-Breaking Fine for Fraud at Steinhoff
- Xi Jinping Warns Dutch PM That 'No Force' Can Stop China's Technological Advancement Amid Export Restrictions
- Taylor Swift Reaches Her Billionaire' Era,' Joining Elon Musk and Jeff Bezos on the List of World's Wealthiest People
- Businessman Brutally Murdered Allegedly by 4 of His Workers Who Swung an Axe Into His Head
- Disney Investor Nelson Peltz Criticizes the Company’s 'Woke' Strategy, Questioning 'Black Panther' and 'The Marvels' Films
- Social Security Benefits to Increase for Some Seniors After Addressing Overpayment Issues
- Major AI Companies Unite to Create the World's First Artificial Superintelligence Alliance Worth $7.6 Billion
- North Korea Refuses Peace Talk With Japan Unless They Confront Their 'Brutal' History; Business Relations at Risk